Antifibrotic combo therapy reduces biomarkers in IPF

A subgroup analysis of the INSTAGE trial shows effects on biomarkers depend on the presence or absence of emphysema

AusDoc brings you the latest news from the European Respiratory Society Congress 2020.

A post-hoc analysis of results from the INSTAGE trial shows that treatment with a combination of nintedanib and sildenafil affects three biomarkers relating to idiopathic pulmonary fibrosis (IPF).

In the INSTAGE trial of people with IPF and a predicted lung diffusion capacity for carbon monoxide (DLCO) of 35% or below, no benefit was found from the combination therapy vs